MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

August 30, 2017

Yury*, 38, is celebrating a moment he thought would never arrive: he has been cured of extensively drug-resistant tuberculosis (XDR-TB). This moment is also a milestone for Doctors Without Borders/Médecins Sans Frontières (MSF): Yury is the first patient to complete MSF’s tuberculosis treatment program in Belarus, run in close cooperation with the Ministry of Health.

February 26, 2016

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.

August 30, 2017

Yury*, 38, is celebrating a moment he thought would never arrive: he has been cured of extensively drug-resistant tuberculosis (XDR-TB). This moment is also a milestone for Doctors Without Borders/Médecins Sans Frontières (MSF): Yury is the first patient to complete MSF’s tuberculosis treatment program in Belarus, run in close cooperation with the Ministry of Health.

February 26, 2016

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.